Innate Pharma SA current report, Q2 FY2021

Business Context and Reporting Period

Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of May 2021
Date of Report: May 25, 2021

This filing serves as a cover document for a press release dated May 25, 2021 (Exhibit 99.1). The registrant is a French company headquartered in Marseille, France, and files annual reports under Form 20-F.

Key Financial Metrics

The provided text is a cover sheet and does not contain specific financial data. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.

Material Changes

No material changes regarding financial performance or operations are detailed in the provided text. The document references a press release (Exhibit 99.1) which likely contains the specific material event, but the content of that release is not included in the input.

Guidance, Outlook, and Risks

The filing text does not provide management commentary, guidance, outlook, risks, contingencies, or details on unusual items. These details are expected to be contained within the referenced press release (Exhibit 99.1).

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release dated May 25, 2021) to identify the specific material event triggering this filing.
  • Verify if the press release contains updates on clinical trial progress, regulatory approvals, or partnership agreements.
  • Check subsequent Form 20-F filings for detailed financial statements and risk factors.